Jieun Oh

Jieun Oh

Auto-generated profile, based on publicly available information

Jieun Oh

University of California, Los Angeles 3 Los Angeles, California

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 November 2021 in Science Advances
Verified
Journal Article
Open access
HFHu Fang
Hu Fang
XZXiaoqiang Zhu
Xiaoqiang Zhu
HYHaocheng Yang
Haocheng Yang
JOJieun Oh
Jieun Oh
JBJayne A. Barbour
Jayne A. Barbour
JWJason W. H. Wong
Jason W. H. Wong
DNA mismatch repair is essential for protecting the human genome from damage induced by 5-methylcytosine deamination.

7 September 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
YPYash Patel
Yash Patel
CZChenghao Zhu
Chenghao Zhu
TYTakafumi N. Yamaguchi
Takafumi N. Yamaguchi
NWNicholas K. Wang
Nicholas K. Wang
NWNicholas Wiltsie
Nicholas Wiltsie
PBPaul C. Boutros
Paul C. Boutros
Summary DNA sequencing is becoming more affordable and faster through advances in high-throughput technologies. This rise in data availability has contributed to the development of novel algorithms to elucidate previously obscure features and led to an increased reliance on complex workflows to integrate such tools into analyses pipelines. To facilitate the analysis of DNA sequencing data, we created metapipeline-DNA, a highly configurable and extensible pipeline. It encompasses a broad range of processing including raw sequencing read alignment and recalibration, variant calling, quality control and subclonal reconstruction. Metapipeline-DNA also contains configuration options to select and tune analyses while being robust to failures. This standardizes and simplifies the ability to analyze large DNA sequencing in both clinical and research settings. Availability Metapipeline-DNA is an open-source Nextflow pipeline under the GPLv2 license and is freely available at https://github.com/uclahs-cds/metapipeline-DNA.

8 February 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
NZNicole Zeltser
Nicole Zeltser
CZChenghao Zhu
Chenghao Zhu
JOJieun Oh
Jieun Oh
CLConstance H. Li
Constance H. Li
PBPaul C. Boutros
Paul C. Boutros
Patient sex influences a wide range of cancer phenotypes, including prevalence, response to therapy and survival endpoints. Molecular sex differences across the central dogma have been identified that may drive these phenotypic differences. Despite a growing catalog of specific genomic, transcriptomic and proteomic sex differences in a range of cancer types, their functional consequences remain unclear. To assess how patient sex impacts cancer cell function, we evaluated 1,209 cell lines subjected to CRISPR knockout, RNAi knockdown or drug exposures. Despite limited statistical power, we identified pan- and per-cancer sex differences in gene essentiality in six sex-linked and fourteen autosomal genes, and in drug sensitivity for two compounds. These data expand our understanding of the propagation of sex-differing molecular features to functional outcomes, and their role in influencing patient phenotypes. They highlight the importance of considering sex-specific effects in mechanistic and functional studies.

17 March 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
CZChenghao Zhu
Chenghao Zhu
NZNicole Zeltser
Nicole Zeltser
JOJieun Oh
Jieun Oh
CLConstance H. Li
Constance H. Li
PBPaul C. Boutros
Paul C. Boutros
Proteins play a central role in cancer biology: they are the most common drug targets and biomarkers. Sex influences the proteome in many diseases, ranging from neurological to cardiovascular. In cancer, sex is associated with incidence, progression and therapeutic response, as well as characteristics of the tumour genome and transcriptome. The extent to which sex differences impact the cancer proteome remains largely unknown. To fill this gap, we quantified sex differences across 1,590 proteomes from eight cancer types, identifying 901 genes with sex-differential proteins abundance in adenocarcinomas of the lung, and 20 genes across five other tumour types: squamous cell carcinoma of the lung, hepatocellular carcinomas, clear cell cancers of the kidney, adenocarcinomas of the pancreas and glioblastoma. A subset of these protein differences could be rationalized by sex-differential copy number aberrations. Pathway analysis showed that male-biased proteins in lung adenocarcinoma were enriched in MYC and E2F target pathways. These findings highlight the modest impact of sex on the cancer proteome, but the very limited power of existing proteomics cohorts for these analyses.

3 November 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
NWNicholas K. Wang
Nicholas K. Wang
NWNicholas Wiltsie
Nicholas Wiltsie
HWHelena K. Winata
Helena K. Winata
SFSorel Fitz-Gibbon
Sorel Fitz-Gibbon
AGAlfredo E. Gonzalez
Alfredo E. Gonzalez
PBPaul C. Boutros
Paul C. Boutros
Reference genomes are foundational to modern genomics. Our growing understanding of genome structure leads to continual improvements in reference genomes and new genome “builds” with incompatible coordinate systems. We quantified the impact of genome build on germline and somatic variant calling by analyzing tumour-normal whole-genome pairs against the two most widely used human genome builds. The average individual had a build-discordance of 3.8% for germline SNPs, 8.6% for germline SVs, 25.9% for somatic SNVs and 49.6% for somatic SVs. Build-discordant variants are not simply false-positives: 47% were verified by targeted resequencing. Build-discordant variants were associated with specific genomic and technical features in variant- and algorithm-specific patterns. We leveraged these patterns to create StableLift, an algorithm that predicts cross-build stability with AUROCs of 0.934 ± 0.029. These results call for significant caution in cross-build analyses and for use of StableLift as a computationally efficient solution to mitigate inter-build artifacts.

5 March 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
TBToby M. Baker
Toby M. Baker
NMNedas Matulionis
Nedas Matulionis
CACassidy Andrasz
Cassidy Andrasz
DGDan Gerke
Dan Gerke
NGNatalia Garcia-Dutton
Natalia Garcia-Dutton
PSPaul Spellman
Paul Spellman
DNA extracted from tissue samples typically derives from a complex mixture of cell types. Without single cell analysis, it has been generally impossible to determine the cell type of origin for most molecules. One clear example of this is in the complex milieu of a human neoplasm. Here, we develop ROCIT ( https://github.com/tobybaker/rocit ), a transformer-based model to classify the tumor or non-tumor origin of individual reads from bulk tumor samples sequenced with long-read whole genome sequencing. Using somatic mutations to derive training data, ROCIT uses read-level methylation patterns to accurately classify reads from any-where in the genome without requiring the adjacent normal tissue or the explicit identification of tumor differentially methylated regions. We apply ROCIT to a cohort of prostate and ovarian tumors and demonstrate high classification accuracy across the entire genome. We then demonstrate the potential of ROCIT predictions to improve somatic variant calling. ROCIT represents a major step forward in the analysis of bulk tumors with long-reads, enabling the accurate and sensitive identification of reads with specific cell types of origin genome-wide.